Search results
Page 1 of 11
Your search for PI3K returned 108 results
Target:
SMG1 nonsense mediated mRNA decay associated PI3K related kinase (SMG1 subfamily)
Name: SMG1 nonsense mediated mRNA decay associated PI3K related kinase
Synonym: SMG1, nonsense mediated mRNA decay associated PI3K related kinase
HGNC gene name: SMG1 nonsense mediated mRNA decay associated PI3K related kinase
MGI gene name: SMG1 nonsense mediated mRNA decay associated PI3K related kinase
RGD gene name: SMG1, nonsense mediated mRNA decay associated PI3K related kinase
Synonym: SMG1, nonsense mediated mRNA decay associated PI3K related kinase
HGNC gene name: SMG1 nonsense mediated mRNA decay associated PI3K related kinase
MGI gene name: SMG1 nonsense mediated mRNA decay associated PI3K related kinase
RGD gene name: SMG1, nonsense mediated mRNA decay associated PI3K related kinase
Target:
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (Phosphatidylinositol-4,5-bisphosphate 3-kinase family, Phosphatidylinositol kinases)
Mutations/pathophysiology - disease: Activated PI3K delta syndrome
Mutations/pathophysiology - disease: Immunodeficiency 14 aka Activated PI3K delta syndrome
Mutations/pathophysiology - disease: p110 delta activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency aka Activated PI3K delta syndrome
Mutations/pathophysiology - disease: APDS/PASLI aka Activated PI3K delta syndrome
3D structure - description: PI3K delta in complex with 2methoxyN[2methoxy5(7{[(2R)4(oxetan3 yl)morpholin2yl]methoxy}1,3dihydro2
Receptor Immuno Comment: PI3K isoform with expression restricted to leukocytes. Genetic and pharmacological inactivation of PI3Kdelta indicates its importantance
Immuno Disease (to Target): Activated PI3K delta syndrome
Mutations/pathophysiology - disease: Immunodeficiency 14 aka Activated PI3K delta syndrome
Mutations/pathophysiology - disease: p110 delta activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency aka Activated PI3K delta syndrome
Mutations/pathophysiology - disease: APDS/PASLI aka Activated PI3K delta syndrome
3D structure - description: PI3K delta in complex with 2methoxyN[2methoxy5(7{[(2R)4(oxetan3 yl)morpholin2yl]methoxy}1,3dihydro2
Receptor Immuno Comment: PI3K isoform with expression restricted to leukocytes. Genetic and pharmacological inactivation of PI3Kdelta indicates its importantance
Immuno Disease (to Target): Activated PI3K delta syndrome
Target:
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (Phosphatidylinositol-4,5-bisphosphate 3-kinase family, Phosphatidylinositol kinases)
Synonym: Pi3k
Synonym: p120-PI3K
3D structure - description: PI3K-gamma in complex with (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin
Receptor Immuno Comment: PI3K isoform has regulatory roles in mediating neutrophil migration (in response to asthmatic epithelial conditioned
Synonym: p120-PI3K
3D structure - description: PI3K-gamma in complex with (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin
Receptor Immuno Comment: PI3K isoform has regulatory roles in mediating neutrophil migration (in response to asthmatic epithelial conditioned
Ligand: bimiralisib
Comments: PI3K) and mechanistic target of rapamycin (mTOR) kinases, with expected utility as an anti-cancer
Mechanism of action: PI3K signaling pathway is frequently activated in tumors and promotes oncogenic cell transformation, proliferation and tumor
Bioactivity comments: PI3K class I isoforms and mTORC1/2 complexes (see AACR poster #2664, 2015). PQR309 exhibits antiproliferative
Mechanism of action: PI3K signaling pathway is frequently activated in tumors and promotes oncogenic cell transformation, proliferation and tumor
Bioactivity comments: PI3K class I isoforms and mTORC1/2 complexes (see AACR poster #2664, 2015). PQR309 exhibits antiproliferative
Target:
RXFP1 (Relaxin family peptide receptors)
Agonists - comment: PI3K mediated pro-migratory phenotype in glioblastoma cell lines and primary cells. Co-immunoprecipitation studies
Transduction - comment: PI3K stimulation. When stimulated by relaxin, RXFP1 activates a number of MAP kinases (including MEK, ERK1/2
Transduction - comment: PI3K-PKCzeta pathway that activates AC5. cAMP accumulation may also occur in response to relaxin
Transduction - comment: PI3K stimulation. When stimulated by relaxin, RXFP1 activates a number of MAP kinases (including MEK, ERK1/2
Transduction - comment: PI3K-PKCzeta pathway that activates AC5. cAMP accumulation may also occur in response to relaxin
Ligand: buparlisib
Comments: where it is compound 15. Buparlisib is a selective and orally bioavailable phosphoinositide 3-kinase (PI3K) inhibitor .
Mechanism of action: PI3K signaling may contribute to tumorigenesis and tumor resistance to a many of the currently
Bioactivity comments: PI3K profile of buparlisib as evaluated by IC50 analysis in kinase assays . At high concentration
Mechanism of action: PI3K signaling may contribute to tumorigenesis and tumor resistance to a many of the currently
Bioactivity comments: PI3K profile of buparlisib as evaluated by IC50 analysis in kinase assays . At high concentration
Ligand: nemiralisib
Comments: PI3K inhibitor with selectivity for PI3Kdelta over the other related isoforms . The compound is active
Clinical use: pulmonary disease (COPD; NCT02522299) or the rare genetic condition activated PI3K-delta syndrome (APDS/PASLI; NCT02593539).
Immuno Disease (to ligand): Activated PI3K delta syndrome
Clinical use: pulmonary disease (COPD; NCT02522299) or the rare genetic condition activated PI3K-delta syndrome (APDS/PASLI; NCT02593539).
Immuno Disease (to ligand): Activated PI3K delta syndrome
Ligand: sonolisib
Comments: kinase (PI3K) with potential antineoplastic activity . It is compound 4 in Zask et al. (2008) .
Mechanism of action: PI3K-induced activation of this pathway by sonolisib, may result in inhibition of tumor cell
Bioactivity comments: inhibit the kinase activity of purified PI3K with IC50 values ranging from 0.1nM to 88nM .
Mechanism of action: PI3K-induced activation of this pathway by sonolisib, may result in inhibition of tumor cell
Bioactivity comments: inhibit the kinase activity of purified PI3K with IC50 values ranging from 0.1nM to 88nM .
Target:
EP4 receptor (Prostanoid receptors)
Functional assay - response measured: Activation of Tcf/Lef signalling via a PI3K-dependent pathway, phosphorylation of GSK-3 and Akt kinase.
Functional assay - response measured: Activation of ERK signalling via a PI3K-dependent pathway and stimulation of EGR-1 expression.
Transduction - comment: A second EP4 signaling pathway is PI3K dependent via G protein Gi activation.
Functional assay - response measured: Activation of ERK signalling via a PI3K-dependent pathway and stimulation of EGR-1 expression.
Transduction - comment: A second EP4 signaling pathway is PI3K dependent via G protein Gi activation.
Target search page 
Ligand search page
Pharmacology search page
